Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM – nejm.org

by

  1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM nejm.org
  2. Lilly links oral drug to 15% weight loss, setting bar for Pfizer FierceBiotech
  3. A new weight-loss drug dubbed the ‘triple G’ could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery Yahoo Life
  4. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet
  5. Novel Triple Agonist Nabs Biggest Weight Loss Yet in Obesity Trial Medpage Today
  6. View Full Coverage on Google News

Read original article here

Leave a Comment